Sarcoma
Welcome,         Profile    Billing    Logout  
 504 Companies   302 Products   302 Products   167 Mechanisms of Action   1357 Trials   122306 News 


«12...345678910111213...15251526»
  • ||||||||||  Clinical, Retrospective data, Review, Journal:  A case report of pediatric biliary botryoid rhabdomyosarcoma. (Pubmed Central) -  Jun 14, 2024   
    Its occurrence in the biliary tract is extremely rare. Due to the high malignancy and rapid metastasis of biliary botryoid rhabdomyosarcoma, early diagnosis and treatment are crucial for improving prognosis.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, Koselugo (selumetinib) / Merck (MSD), AstraZeneca
    Trial completion date, Trial primary completion date:  Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas (clinicaltrials.gov) -  Jun 13, 2024   
    P2,  N=41, Not yet recruiting, 
    Due to the high malignancy and rapid metastasis of biliary botryoid rhabdomyosarcoma, early diagnosis and treatment are crucial for improving prognosis. Trial completion date: Jun 2030 --> Dec 2030 | Trial primary completion date: Jun 2029 --> Dec 2029
  • ||||||||||  Clinical, Journal, IO biomarker:  Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma. (Pubmed Central) -  Jun 13, 2024   
    Furthermore, CRISPRa experiments implicated the transcription factor FOSL1 in activating sRCC-associated gene regulatory programs, and FOSL1 expression was associated with the response to ICIs in RCC in two randomized clinical trials. Finally, we established a blood-based diagnostic approach using detectable sRCC epigenomic signatures in patient plasma, providing a framework for discovering epigenomic correlates of tumor histology via liquid biopsy.
  • ||||||||||  Journal, Metastases:  Myxoid Liposarcoma Metastasizing to the Parotid Gland. (Pubmed Central) -  Jun 13, 2024   
    However, this mass was confirmed to be metastasis of MLPS through immunohistochemistry and multicolor fluorescence in situ hybridization. The authors report a case in which an MLPS metastasized to the parotid gland; this type of lesion is extremely rare and highly worthy of consideration because the authors misdiagnosed it.
  • ||||||||||  Biomarker, Journal:  Identification the role of necroptosis in rheumatoid arthritis by WGCNA network. (Pubmed Central) -  Jun 13, 2024   
    The close association between the concentrations of various immune cells is anticipated to contribute to the diagnosis and treatment of RA. Furthermore, the infiltration of immune cells mentioned earlier is likely to exert a substantial influence on the initiation of this disease.
  • ||||||||||  Journal:  Primary synovial sarcoma in anal canal: Report of a very rare case. (Pubmed Central) -  Jun 13, 2024   
    Extensive studies are required to understand the behavior as well as prognosis of SS in the colorectal region. IHC staining is essential for the accurate diagnosis when a lesion is encountered at an unusual site.
  • ||||||||||  Preclinical, Journal:  Kaposi sarcoma-associated herpesvirus complement control protein (KCP) and glycoprotein K8.1 are not required for viral infection in vitro or in vivo. (Pubmed Central) -  Jun 13, 2024   
    Using newly generated anti-KCP antibodies, previously characterized anti-K8.1 antibodies, and recombinant mutant KSHV viruses lacking KCP and/or K8.1, we show that KCP and K8.1 can be found on the surface of both virions and KSHV-infected cells. Furthermore, we show that KSHV lacking KCP and/or K8.1 remains infectious to diverse cell types susceptible to KSHV in vitro and to human B cells in vivo in a humanized mouse model, thus providing evidence that these viral glycoproteins are not required for KSHV infection.
  • ||||||||||  Journal:  Clinical course of asymptomatic duodenal subepithelial lesions. (Pubmed Central) -  Jun 13, 2024   
    An initial size of 20 mm or larger was associated with substantial changes during follow-up (p = 0.016). While the majority of duodenal SELs may not exhibit substantial interval changes, regular follow-up with endoscopy may be necessary for cases with an initial size of 20 mm or larger, considering a possibility of malignancy.
  • ||||||||||  Journal, Stroma:  Surgical management of gastrointestinal stromal tumors of gastric origin (Pubmed Central) -  Jun 13, 2024   
    Surgery remains the only curative treatment, while tyrosine kinase inhibitors have demonstrated their efficacy as systemic treatment in the perioperative context. Risk stratification for recurrence guides the choice of adjuvant treatment, with a recommended duration of 3 years for high-risk patients.
  • ||||||||||  Clinical, Clinical protocol, Observational data, Preclinical, Retrospective data, Review, Clinical Trial,Phase III, Journal:  Liposarcomas of the pharynx: A case report. (Pubmed Central) -  Jun 12, 2024   
    Further studies are warranted to explore the clinical utility of 5-ALA PDT in preventing DFSP recurrence. No abstract available
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, Metastases:  Metastatic glioblastoma to the lungs: a case report and literature review. (Pubmed Central) -  Jun 12, 2024   
    This case contributes to the growing body of evidence for the role of genomic alterations in predictive risk in metastatic glioblastoma. There remains an unmet need for treatment of metastatic glioblastoma.
  • ||||||||||  Mycobutin (rifabutin) / Pfizer, Lupin
    Journal:  Opportunistic Infections and Malignancies in a Patient With HIV/AIDS and a Critically Low CD4 Count of 1 Cell/?L. (Pubmed Central) -  Jun 12, 2024   
    This case uniquely highlights the wide range of opportunistic infections and malignancies that can present in individuals with advanced-stage HIV/AIDS, underscoring the importance of early recognition and treatment. This susceptible demographic warrants further research due to the non-solidified prognosis of individuals with severe immunodeficiency.
  • ||||||||||  Ogsiveo (nirogacestat) / SpringWorks Therap
    Review, Journal:  Capturing Patient Voice to Improve Outcomes That Matter to Patients with Desmoid Tumor. (Pubmed Central) -  Jun 12, 2024   
    Another DT-specific PRO measure, the Desmoid-Type Fibromatosis Quality of Life (DTF-QoL) questionnaire, has been developed but not validated. As novel DT therapies continue to be developed, incorporating DT-specific PRO measures into clinical trials will be key to capturing patient voice, improving outcomes of importance to this unique patient population, and assisting patients and providers in selecting optimal treatment.
  • ||||||||||  metformin / Generic mfg.
    Review, Journal:  Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways. (Pubmed Central) -  Jun 12, 2024   
    Moreover, MET can stimulate autophagy through pathways associated with the 5' AMPK, thereby inhibiting he development and progression of various human cancers, including hepatocellular carcinoma, prostate cancer, pancreatic cancer, osteosarcoma, myeloma, and non-small cell lung cancer. In summary, this detailed review provides a framework for further investigations that may appraise the autophagy-induced anticancer potential of MET and its repurposing for cancer treatment.
  • ||||||||||  mocetinostat (MGCD0103) / Otsuka, BMS
    Trial completion date, Trial primary completion date, Combination therapy:  Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma (clinicaltrials.gov) -  Jun 11, 2024   
    P1,  N=38, Recruiting, 
    In summary, this detailed review provides a framework for further investigations that may appraise the autophagy-induced anticancer potential of MET and its repurposing for cancer treatment. Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2024 --> May 2025
  • ||||||||||  cisplatin / Generic mfg.
    Journal:  Optimizing ATR inhibition and cisplatin synergy in Ewing sarcoma. (Pubmed Central) -  Jun 11, 2024   
    EWSR1::FLI1-mediated dysregulation of cellular machinery opens up potential new avenues for Ewing sarcoma treatment. A recent study demonstrates that pharmacological ATR kinase inhibition dramatically synergizes with low-dose cisplatin through EWSR1::FLI1-dependent rewiring of transcription, DNA repair, and translation machinery, which could maximize the therapeutic window of the combinatory therapy.